Please select the option that best describes you:
Topics:
Thoracic Malignancies • Medical Oncology
In light of recent retrospective data from France on EGFR TKIs use with PPIs showing negative outcomes in NSCLC patients would you consider discontinuing PPIs or changing PPIs to H2 inhibitors?
https://www.sciencedirect.com/science/article/pii/S2468294224000133?via%3Dihub